PA
STKL

PharVision Advisers’s SunOpta STKL Stock Holding History

PharVision Advisers’s Portfolio STKL Stock Details STKL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,628
Closed -$90.6K – 790
2025
Q2 		$90.6K Buy
+15,628
New +$82.1K 0.13% 256
2025
Q1 		– Sell
-19,857
Closed -$153K – 499
2024
Q4 		$153K Buy
+19,857
New +$140K 0.13% 344

Other funds holding STKL

OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TIM
Thornburg Investment Management Santa Fe, New Mexico $9.63B AUM 35.65% 1-Year Est. Return

PharVision Advisers's STKL Position: Q3 2025 in Review

PharVision Advisers sold out of SunOpta (STKL) in Q3 2025, closing a stake of 15,628 shares — an estimated $90.6K sold.

PharVision Advisers first reported a position in STKL in Q4 2024 and held it in 2 quarters. The position peaked at $153K in Q4 2024. 204 funds tracked by Wall St. Rank hold STKL as of Q3 2025.

  • PharVision Advisers reported no remaining SunOpta position as of Q3 2025 after selling out during the quarter.
  • PharVision Advisers sold 15,628 SunOpta shares in Q3 2025, an estimated $90.6K.
  • PharVision Advisers first reported a position in SunOpta in Q4 2024 and held it in 2 quarters.
  • PharVision Advisers's SunOpta position peaked at $153K in Q4 2024.
  • 204 funds tracked by Wall St. Rank held SunOpta as of Q3 2025.

Based on PharVision Advisers's 13F filing for Q3 2025, filed 17 Nov 2025.